The immunology of posttransplant CMV infection: Potential effect of CMV immunoglobulins on distinct components of the immune response to CMV

Transplantation

Volumn 100, Issue , 2016, Pages S11-S18

  Carbone, Javier ^a  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOMEGALOVIRUS ANTIBODY; ANTIVIRUS AGENT; CYTOMEGALOVIRUS-SPECIFIC HYPERIMMUNE GLOBULIN; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; VIRUS ANTIBODY;

ADAPTIVE IMMUNITY; ARTICLE; B LYMPHOCYTE; CELLULAR IMMUNITY; CYTOMEGALOVIRUS INFECTION; DENDRITIC CELL; DISEASE COURSE; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOLOGY; IMMUNOMODULATION; INNATE IMMUNITY; LYMPHOCYTE SUBPOPULATION; MOUSE; NONHUMAN; ORGAN TRANSPLANTATION; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; VIREMIA; VIRUS DETECTION; VIRUS NEUTRALIZATION; ADVERSE EFFECTS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DRUG EFFECTS; HEART TRANSPLANTATION; HOST PATHOGEN INTERACTION; IMMUNOCOMPROMISED PATIENT; LUNG TRANSPLANTATION; LYMPHOCYTE; OPPORTUNISTIC INFECTIONS; TIME FACTOR; TREATMENT OUTCOME; VIROLOGY; VIRUS ACTIVATION;

ADAPTIVE IMMUNITY; ANTIBODIES, VIRAL; ANTIVIRAL AGENTS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; HEART TRANSPLANTATION; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; IMMUNITY, INNATE; IMMUNIZATION, PASSIVE; IMMUNOCOMPROMISED HOST; IMMUNOGLOBULINS; IMMUNOSUPPRESSIVE AGENTS; LUNG TRANSPLANTATION; LYMPHOCYTES; OPPORTUNISTIC INFECTIONS; TIME FACTORS; TREATMENT OUTCOME; VIRUS ACTIVATION;

EID: 84959882546     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0000000000001095     Document Type: Article

References (72)

1. Boehme KW, Guerrero M, Compton T. Human cytomegalovirus envelope glycoproteins B and H are necessary for TLR2 activation in permissive cells. J Immunol. 2006;177:7094-7102.
2. Smith PD, Shimamura M, Musgrove LC, et al. Cytomegalovirus enhances macrophage TLR expression and MyD88-mediated signal transduction to potentiate inducible inflammatory responses. J Immunol. 2014;193:5604-5612.
3. Kijpittayarit S, Eid AJ, Brown RA, et al. Relationship between Toll-like receptor 2 polymorphism and cytomegalovirus disease after liver transplantation. Clin Infect Dis. 2007;44:1315-1320.
4. Kang SH, Abdel-Massih RC, Brown RA, et al. Homozygosity for the Tolllike receptor 2 R753Q single-nucleotide polymorphism is a risk factor for cytomegalovirus disease after liver transplantation. J Infect Dis. 2012;205:639-646.
5. Stern M, Elsässer H, Hönger G, et al. The number of activating KIR genes inversely correlates with the rate of CMV infection/reactivation in kidney transplant recipients. Am J Transplant. 2008;8:1312-1317.
6. hi natural killer cell subset during acute human cytomegalovirus infection. Proc Natl Acad Sci U S A. 2011;108:14725-14732.
7. Costa-Garcia M, Vera A, Moraru M, et al. Antibody-mediated response of NKG2Cbright NK cells against human cytomegalovirus. J Immunol. 2015;194:2715-2724.
8. Stacey MA, Marsden M, Pham N T A, et al. Neutrophils recruited by IL-22 in peripheral tissues function as TRAIL-dependent antiviral effectors against MCMV. Cell Host Microbe. 2014;15:471-483.
9. Gerna G, Sarasini A, Patrone M, et al. Human cytomegalovirus serum neutralizing antibodies block virus infection of endothelial/epithelial cells, but not fibroblasts, early during primary infection. J Gen Virol. 2008;89(Pt 4):853-865.
10. Dasari V, Smith C, Zhong J, et al. Recombinant glycoprotein B vaccine formulation with Toll-like receptor9 agonist and immune-stimulating complex induces specific immunity against multiple strains of cytomegalovirus. J Gen Virol. 2011;92(Pt 5):1021-1031.
11. Genini E, Percivalle E, Sarasini A, et al. Serum antibody response to the gH/gL/pUL128-131 five-protein complex of human cytomegalovirus (HCMV) in primary and reactivated HCMV infections. J Clin Virol. 2011;52:113-118.
12. Ishibashi K, Tokumoto T, Shirakawa H, et al. Lack ofantibodies against the antigen domain 2 epitope of cytomegalovirus (CMV) glycoprotein B is associated with CMV disease after renal transplantation in recipients having the same glycoprotein H serotypes as their donors. Transpl Infect Dis. 2011;13:318-323.
13. Carbone J, Rodriguez-Molina J, Navarro J, et al. CMV-seronegative heart recipients disclose a lower immunocompetence status before transplantation in comparison with seropositive patients. J Heart Lung Transplant. 2014;33(Supplement):S20.
14. Hughes D, Hafferty J, Fulton L, et al. Donor and recipient CMV serostatus and antigenemia after renal transplantation: an analysis of 486 patients. J Clin Virol. 2008;41:92-95.
15. Jacob CL, Lamorte L, Sepulveda E, et al. Neutralizing antibodies are unable to inhibit direct viral cell-to-cell spread of human cytomegalovirus. Virology. 2013;444:140-147.
16. Ohta A, Fujita A, Murayama T, et al. Recombinant human monoclonal antibodies to human cytomegalovirus glycoprotein B neutralize virus in a complement-dependent manner. Microbes Infect. 2009;11:1029-1036.
17. Spiller OB, Hanna SM, Devine DV, et al. Neutralization of cytomegalovirus virions: the role of complement. J Infect Dis. 1997;176:339-347.
18. Sylwester AW, Mitchell BL, Edgar JB, et al. Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects. J Exp Med. 2005;202:673-685.
19. Sester M, Sester U, Gärtner BC, et al. Dominance of virus-specific CD8 T cells in human primary cytomegalovirus infection. J Am Soc Nephrol. 2002;13:2577-2584.
20. van Leeuwen EM, Remmerswaal EB, Vossen MT, et al. Emergence of a CD4+CD28-granzyme B+, cytomegalovirus-specific T cell subset after recovery of primary cytomegalovirus infection. J Immunol. 2004;173:1834-1841.
21. Rowshani AT, Bemelman FJ, van Leeuwen EM, et al. Clinical and immunologic aspects of cytomegalovirus infection in solid organ transplant recipients. Transplantation. 2005;79:381-386.
22. Jin X, Demoitie MA, Donahoe SM, et al. High frequency of cytomegalovirusspecific cytotoxic T-effector cells in HLA-A∗0201-positive subjects during multiple viral coinfections. J Infect Dis. 2000;181:165-175.
23. Sester U, Gärtner BC, Wilkens H, et al. Differences in CMV-specific T-cell levels and long-term susceptibility to CMV infection after kidney, heart and lung transplantation. Am J Transplant. 2005;5:1483-1489.
24. Kotton CN, Kumar D, Caliendo AM, et al. Updated international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation. Transplantation. 2013;96:333-360.
25. Lúcia M, Crespo E, Melilli E, et al. Preformed frequencies of cytomegalovirus (CMV)-specific memory T and B cells identify protected CMV-sensitized individuals among seronegative kidney transplant recipients. Clin Infect Dis. 2014;59:1537-1545.
26. Dirks J, Tas H, Schmidt T, et al. PD-1 analysis on CD28 (-) CD27 (-) CD4 T cells allows stimulation-independent assessment of CMV viremic episodes in transplant recipients. Am J Transplant. 2013;13:3132-3141.
27. Ahlenstiel-Grunow T, Koch A, Großhennig A, et al. A multicenter, randomized, open-labeled study to steer immunosuppressive and antiviral therapy by measurement of virus (CMV, ADV, HSV)-specific T cells in addition to determinationof trough levels of immunosuppressants in pediatric kidney allograft recipients (IVIST01-trial): study protocol for a randomized controlled trial. Trials. 2014;15:324.
28. Manuel O, Kralidis G, Mueller NJ, et al. Impact of antiviral preventive strategies on the incidence and outcomes of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant. 2013;13:2402.
29. Manuel O, Husain S, Kumar D, et al. Assessment of cytomegalovirusspecific cell-mediated immunity for the prediction of cytomegalovirus disease in high-risk solid-organ transplant recipients: a multicenter cohort study. Clin Infect Dis. 2013;56:817-824.
30. Sester M, Sester U, Gärtner B, et al. Levels of virus-specific CD4 T cells correlate with cytomegalovirus control and predict virus-induced disease after renal transplantation. Transplantation. 2001;71:1287-1294.
31. Keven K, Sahin M, Kutlay S, et al. Immunoglobulin deficiency in kidney allograft recipients: comparative effects of mycophenolate mofetil and azathioprine. Transpl Infect Dis. 2003;5:181-186.
32. Kobashigawa J, Ross H, Bara C, et al. Everolimus is associated with a reduced incidence of cytomegalovirus infection following de novo cardiac transplantation. Transpl Infect Dis. 2013;15:150-162.
33. Brennan DC, Legendre C, Patel D, et al. Cytomegalovirus incidence between everolimus versus mycophenolate in de novo renal transplants: pooled analysis of three clinical trials. Am J Transplant. 2011;11:2453-2462.
34. Mourad G, Rostaing L, Legendre C, et al. Sequential protocols using basiliximab versus antithymocyte globulins in renal-transplant patients receiving mycophenolate mofetil and steroids. Transplantation. 2004;78:584-590.
35. Abou-Ayache R, Büchler M, Lepogamp P, et al. CMV infections after two doses of daclizumab versus thymoglobulin in renal transplant patients receiving mycophenolate mofetil, steroids and delayed cyclosporine A. Nephrol Dial Transplant. 2008;23:2024-2032.
36. Krogsgaard K, Boesgaard S, Aldershvile J, et al. Cytomegalovirus infection rate among heart transplant patients in relation to anti-thymocyte immunoglobulin induction therapy. Copenhagen Heart Transplant Group. Scand J Infect Dis. 1994;26:239-247.
37. Huurman VA, Kalpoe JS, van de Linde P, et al. Choice of antibody immunotherapy influences cytomegalovirus viremia in simultaneous pancreaskidney transplant recipients. Diabetes Care. 2006;29:842-847.
38. Watkins RR, Lemonovich TL, Razonable RR. Immune responseto CMV in solid organ transplant recipients: current concepts and future directions. Expert Rev Clin Immunol. 2012;8:383-393.
39. Carbone J, Lanio N, Gallego A, et al. Simultaneous monitoring of cytomegalovirus-specific antibody and T-cell levels in seropositive heart transplant recipients. J Clin Immunol. 2012;32:809-819.
40. Sarmiento E, del Pozo N, Gallego A, et al. Decreased levels ofserum complement C3 and natural killer cells add to the predictive value of total immunoglobulin G for severe infection in heart transplant recipients. Transpl Infect Dis. 2012;14:526-539.
41. Sarmiento E, Navarro J, Fernandez-Yañez J, et al. Evaluation of an immunological score to assess the risk of severe infection in heart recipients. Transpl Infect Dis. 2014;16:802-812.
42. Sarmiento E, Lozano F, Del Pozo N, et al. Risk of CMV infection in heart recipients: usefulness of mannose-binding lectin serum levels and genotypes. Madrid Abstract. ESOT + AST meeting. 2014.
43. Carbone J, Arraya M, Lozano F, et al. Mannose-binding lectin serum levels and pre-transplant genotypes for personalized anti-CMV prophylaxis in heart recipients. J Heart Lung Transplant. 2015;34:S125.
44. Florescu DF, Kalil AC, Qiu F, et al. What is the impact of hypogammaglobulinemia on the rate of infections and survival in solid organ transplantation? A meta-analysis. Am J Transplant. 2013;13:2601-2610.
45. Sarmiento E, Rodríguez-Molina J, Muñoz P, et al. Decreased levels of serum immunoglobulins as a risk factor for infection after heart transplantation. Transplant Proc. 2005;37:4046-4049.
46. Corales R, Chua J, Mawhorter S, et al. Significant post-transplant hypogammaglobulinemia in six heart transplant recipients: an emerging clinical phenomenon? Transpl Infect Dis. 2000;2:133-139.
47. Doron S, Ruthazer R, Werner BG, et al. Hypogammaglobulinemia in liver transplant recipients: Incidence, timing, risk factors, and outcomes. Transplantation. 2006;81:697-703.
48. Sarmiento E, Lanio N, Gallego A, et al. Immune monitoring of anti cytomegalovirus antibodies and risk of cytomegalovirus disease in heart transplantation. Int Immunopharmacol. 2009;9:649-652.
49. Sarmiento E, Jaramillo M, Navarro J, et al. Humoral immunity profiles to identify CMV-seropositive heart recipients at risk of CMV disease: a prospective multicenter study. J Heart Lung Transplant. 2014; (Suppl): S20 [Abstract 33].
50. Sarmiento E, Rodriguez-Molina JJ, Fernandez-Yañez J, et al. IgG monitoring to identify the risk for development of infection in heart transplant recipients. Transpl Infect Dis. 2006;8:49-53.
51. Yamani MH, Avery R, Mawhorter S, et al. Hypogammaglobulinemia after heart transplantation: impact of pre-emptive use of immunoglobulin replacement (CytoGam) on infection and rejection outcomes. Transpl Infect Dis. 2001;3(Suppl 2):40-43.
52. Presser D, Sester U, Mohrbach J, et al. Differential kinetics of effector and regulatory Tcells in patients on calcineurin inhibitor-based drug regimens. Kidney Int. 2009;76:557-566.
53. Tu W, Potena L, Stepick-Biek P, et al. T-cell immunity to subclinical cytomegalovirus infection reduces cardiac allograft disease. Circulation. 2006;114:1608-1615.
54. Egli A, Binet I, Binggeli S, et al. Cytomegalovirus-specific T-cell responses and viral replication in kidney transplant recipients. J Transl Med. 2008;6:29.
55. Abate D, Fiscon M, Saldan A, et al. Human cytomegalovirus-specific T-cell immune reconstitution in preemptively treated heart transplant recipients identifies subjects at critical risk for infection. J Clin Microbiol. 2012;50:1974-1980.
56. San Juan R, Aguado JM, RESITRA Network, Spain. Incidence, clinical characteristics and risk factors of late infection in solid organ transplant recipients: data from the RESITRA study group. Am J Transplant. 2007;7:964-971.
57. Fouts AE, Chan P, Stephan JP, et al. Antibodies against the gH/gL/UL128/UL130/UL131 complex comprise the majority of the anti-cytomegalovirus (anti-CMV) neutralizing antibody response in CMV hyperimmune globulin. J Virol. 2012;86:7444-7447.
58. Kwekkeboom J, Tha-In T, Tra WM, et al. Hepatitis B immunoglobulins inhibit dendritic cells and Tcells and protect against acute rejection after liver transplantation. Am J Transplant. 2005;5:2393-2402.
59. Cytotect® Summary of Product Characteristics, Biotest AG, Dreieich, Germany. Updated November 2012.
60. Ganzinger U, Martindale JJ, Gaudera E, et al. Pharmacokineticsofananticytomegalovirus hyperimmunoglobulin after single intravenous administration to healthy volunteers. Vox Sang. 1991;60:203-206.
61. Planitzer CB, Saemann MD, Gajek H, et al. Cytomegalovirus neutralization by hyperimmune and standard intravenous immunoglobulin preparations. Transplantation. 2011;92:267-270.
62. Denys C, Toungouz M, Dupont E. Increased in vitro immunosuppressive action of anti-CMV and anti-HBs intravenous immunoglobulins due to higher amounts of interferon-gamma specific neutralizing antibodies. Vox Sang. 1997;72:247-250.
63. Filipovich AH, Peltier MH, Bechtel MK, et al. Circulating cytomegalovirus (CMV) neutralizing activity in bone marrow transplant recipients: comparison of passive immunity in a randomized study of four intravenous IgG products administered to CMV-seronegative patients. Blood. 1992;80:2656-2660.
64. Adler SP. Neutralizing activity of immunoglobulin preparations. Transplantation. 2012;93:e14.
65. Yamani MH, Avery R, Mawhorter SD, et al. The impact of Cytogam oncardiac transplant recipients with moderate hypogammaglobulinemia: a randomized single-center study. J Heart Lung Transplant. 2005;24:1766-1769.
66. Gerna G, Lilleri D, Fornara C, et al. Differential kinetics of human cytomegalovirus load and antibody responses in primary infection of the immunocompetent and immunocompromised host. J Gen Virol. 2015;96(Pt 2):360-369.
67. Hoetzenecker K, Hacker S, Hoetzenecker W, et al. Cytomegalovirus hyperimmunoglobulin: mechanisms in allo-immune response in vitro. Eur J Clin Invest. 2007;37:978-986.
68. van Gent R, Jaadar H, Tjon AS, et al. T-cell inhibitory capacity of hyperimmunoglobulins is influenced by the production process. Int Immunopharmacol. 2014;19:142-144.
69. Klaesson S, Ringdén O, Markling L, et al. Immune modulatory effects of immunoglobulins on cell-mediated immune responses in vitro. Scand J Immunol. 1993;38:477-484.
70. Solidoro P, Libertucci D, Delsedime L, et al. Combined cytomegalovirus prophylaxis in lung transplantation: effects on acute rejection, lymphocytic bronchitis/bronchiolitis, and herpesvirus infections. Transplant Proc. 2008;40:2013-2014.
71. Bonaros N, Mayer B, Schachner T, et al. CMV-hyperimmune globulin for preventing cytomegalovirus infection and disease in solid organ transplant recipients: a meta-analysis. Clin Transplant. 2008;22:89-97.
72. Farges O, Saliba F, Farhamant H, et al. Incidence of rejection and infection after liver transplantation as a function of the primary disease: possible influence of alcohol and polyclonal immunoglobulins. Hepatology. 1996;23:240-248.